Forchheim, Germany Clinical Trials

A listing of Forchheim, Germany clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 130 clinical trials
Cardiac Resynchronization Therapy in Previously Untreatable and High Risk Upgrade Patients

This study is a prospective, multi-center, pivotal trial to study the safety and efficacy of the WiSE-CRT System for Cardiac Re-synchronization Therapy.

medical therapy
left bundle branch block
cardiac resynchronization therapy
Universit tsklinikum Erlangen
 (8.7 away) Contact site
  • 16 Feb, 2021
  • +68 other locations
Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

This trial studies ladiratuzumab vedotin (LV) with pembrolizumab in patients with triple-negative breast cancer. It will find out what side effects happen when participants get these two drugs. A side effect is anything the drugs do besides treating cancer. Pembrolizumab is a drug that can be used to treat triple-negative …

advanced breast cancer
stage iv breast cancer
breast cancer
Universit tsklinikum Erlangen
 (8.7 away) Contact site
  • 20 Jul, 2021
  • +59 other locations
Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy

The study goal is to determine the clinical benefit of percutaneous catheter-based left atrial appendage (LAA) closure in patients with non-valvular atrial fibrillation (NVAF) at high risk of stroke (CHA2DS2-VASc Score 2) as well as high risk of bleeding as compared to best medical care (including a [non-vitamin K] oral …

left atrial appendage closure
Universit tsklinikum Erlangen, Medizinische Klinik II - Kardiologie und Angiologie
 (8.7 away) Contact site
  • 04 Aug, 2021
  • +43 other locations
A Multicenter Randomized Double-Blind Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis

The objectives of Sub-Study 1 are to evaluate the efficacy, safety, and pharmacokinetics of risankizumab as induction treatment in subjects with moderately to severely active ulcerative colitis (UC), and to identify the appropriate induction dose of risankizumab for further evaluation in Sub-Study 2. The objective of Sub-Study 2 is to …

Universitaetsklinikum Erlangen /ID# 159354
 (8.7 away) Contact site
  • 04 Aug, 2021
  • +890 other locations
Randomization of Single vs Multiple Arterial Grafts

The primary hypothesis of ROMA is that in patients undergoing primary isolated non-emergent coronary artery bypass surgery (CABG), the use of two or more arterial grafts compared to a single arterial graft is associated with a reduction in the composite outcome of death from any cause, any stroke, post discharge …

bypass graft
bypass surgery
myocardial infarction
University Hospital Erlangen
 (9.4 away) Contact site
  • 28 May, 2021
  • +56 other locations
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

The understanding of acute lymphoblastic leukemia (ALL) in childhood and adolescence has largely changed due to extensive genetic research in recent years: ALL is now considered to be a very heterogeneous disease group. The leukemia cells present themselves with quite differently activated regulatory mechanisms of the malignant phenotype. The introduction …

lymphoid leukemia
acute leukemia
adult t-cell leukemia/lymphoma
Universitaets - Kinderklinik
 (8.7 away) Contact site
  • 18 Jul, 2021
  • +168 other locations
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who roll-over into this extension study. This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-up Phase or 3) Second Course Phase. …

major surgery
Universit tsklinikum Erlangen ( Site 2408)
 (8.7 away) Contact site
  • 05 Aug, 2021
  • +267 other locations
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) versus placebo in combination with neoadjuvant (pre-surgery) chemotherapy and adjuvant (post-surgery) endocrine therapy in the treatment of adults who have high-risk early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer. The primary …

endocrine therapy
epidermal growth factor
hormone therapy
core needle biopsy
Universitaetsklinikum Erlangen ( Site 1001)
 (8.7 away) Contact site
  • 05 Aug, 2021
  • +286 other locations
A Study Testing How BI 655130 Works in Patients With Fistulizing Crohn's Disease

This is a study in adults with Crohn's Disease who also have fistulas near the anus. The study has 2 parts. The first part is to find out more about what causes the fistulas. In this part of the study, tissue samples are taken from patients. The second part of …

bowel resection
tumor necrosis factor alpha
Universit tsklinikum Erlangen
 (8.7 away) Contact site
  • 21 Jul, 2021
  • +18 other locations
Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study of the efficacy and safety of apremilast (CC-10004) in pediatric subjects with moderate to severe plaque psoriasis. At least 230 pediatric subjects (ages 6 through 17 years) will be randomized 2:1 to receive either apremilast or placebo for the first …

systemic therapy
topical agents
plaque psoriasis
Universitatsklinikum Erlangen
 (9.5 away) Contact site
  • 04 Aug, 2021
  • +284 other locations